Browse studies

Find your next paid study

136 recruiting studies matching your filters

Feasibility of Treating Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma With Zanubrutinib in Combination With the BCL2 Inhibitor, Sonrotoclax, Focusing on Access for Underrepresented Ethnic/Racial Minorities

This phase I trial tests zanubrutinib in combination with sonrotoclax for treating underrepresented ethnic and racial minorities with B-cell non-Hodgkin lympho…

Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell Lymphoma+16 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

City of Hope Medical CenterNCT06859008

Phase 2

Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma

The purpose of this research study is to see how metformin, when used in combination with standard of care (SOC) treatment for metastatic (cancer that has spre…

Sarcoma MetastaticSarcoma, Soft Tissue

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Wake Forest University Health SciencesNCT07291297

Phase 2

A Phase II Study of BIO 300 to Reduce the Toxicity of Thoracic Radiotherapy for Patients With Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease (BREATHE)

The purpose of this study to find out whether giving BIO 300 in combination with thoracic radiation therapy is effective in preventing pneumonitis in people wi…

NSCLCNSCLC, Stage INSCLC Stage II+5 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT07323732

Phase 1

Phase 1b/2a Clinical Study of Catequentinib Hydrochloride (AL3818) Monotherapy or Combining Therapy With Other Anti-tumor Agents in Advanced, Metastatic Endometrial, Low Grade Serous Ovarian Cancer (LGSOC), STS or GBM Cancers

This phase 1b/2a study evaluates the investigational oral drug catequentinib hydrochloride (AL3818), given alone or with AL58805, temozolomide, or lomustine (C…

Endometrial NeoplasmsOvarian NeoplasmsSoft Tissue Sarcoma (STS)+1 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Advenchen Pharmaceuticals, LLC.NCT07811297

Phase 3

A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adults With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (INVINCIBLE-3)

To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undiffe…

Sarcoma,Soft Tissue

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Intensity Therapeutics, Inc.NCT06263231

Phase 2

Evaluating the Impact of Limited vs. Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Soft Tissue Sarcoma

This phase II trial studies how anxiety is affected by 2 types of follow-up after surgery, limited follow-up and intense follow-up, in patients with stage II-I…

Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8+1 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

M.D. Anderson Cancer Center

Phase 1

Intraoperative Evaluation of Blood Flow for Knee Arthroscopy Using Indocyanine Green Fluorescence Angiography

The purpose of this study is to first evaluate whether ICG fluorescence angiography can be used to evaluate blood flow of the anterior cruciate ligament (ACL),…

To Assess the Feasibility, Visualization Capability, and Optimal Dosing of ICG Fluorescence Imaging for Intraoperative Assessment of Knee Tissue Perfusion

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Henry Ford Health SystemNCT07793266

Phase 1

Phase I Study of HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0)

The purpose of this study is to learn whether it is safe to give HER2-CAR T cells in combination with an immune checkpoint inhibitor drug (pembrolizumab or niv…

SarcomaHER-2 Protein OverexpressionOsteosarcoma+5 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Baylor College of MedicineNCT04995003

Pediatric PET/MR Image Registry

The purpose of this study is to compare whole body magnetic resonance (MR) imaging, whole body positron emission tomography (PET)/MR imaging, and (if available…

Soft TissueLymphomaOsteosarcoma

Estimated

~$10 – $750

Actual pay is set by the research site.

Stanford UniversityNCT03458520

Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial Hypertension (PAH)

The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulm…

Idiopathic Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionPulmonary Arterial Hypertension Associated With Connective Tissue Disease

Estimated

~$10 – $750

Actual pay is set by the research site.

Vanderbilt University Medical CenterNCT05462574

Undifferentiated Connective Tissue Disease Registry

This registry has been established to gain a better understanding of the clinical and emotional presentations of patients with undifferentiated connective tiss…

Undifferentiated Connective Tissue Disease

Estimated

~$10 – $750

Actual pay is set by the research site.

Hospital for Special Surgery, New YorkNCT02234388

Probing Participation in Soft Tissue Sarcoma Research: An Observational Study of Soft Tissue Sarcoma Clinical Trials

Generally, specific demographic cohorts exhibit higher participation rates in medical research, yet there exists a scarcity of research elucidating the trial a…

Soft Tissue Sarcoma

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Power Life Sciences Inc.NCT06264505